GleamWall
中文EN

ACHV ACHIEVE LIFE SCIENCES, INC.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 949858 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-113.4%
TTM EPS YoY-4.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-104.2%
ROA-86.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets12.4%
Debt / equity0.00x
Current ratio10.49x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.39x
Accruals ratio-52.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense————$5.32M$6.71M$7.10M$7.30M
SG&A expense————$9.37M$5.86M$5.80M$4.89M
Interest expense$258,000$277,000$274,000$251,000$192,000$191,000$185,000$197,000
Net income-$12.11M-$74.77M-$10.17M-$14.66M-$14.44M-$12.72M-$12.83M-$12.36M
EPS (basic)-0.11-0.80-0.19—-0.28-0.37-0.37—
EPS (diluted)-0.11-0.80-0.19—-0.28-0.37-0.37—
Weighted avg. shares (diluted)105.48M93.51M53.38M—51.02M34.69M34.69M—
Balance sheet
Cash & equivalents$59.74M$47.96M$28.08M$20.93M$31.93M$51.87M$13.02M$12.75M
Short-term investments$141.78M$139.34M$1.19M$15.47M$16.18M$3.52M$10.23M$21.61M
Current assets$203.41M$188.29M$31.06M$39.89M$50.05M$56.90M$25.00M$36.47M
PP&E, net———$3,000———$8,000
Goodwill$1.03M$1.03M$1.03M$1.03M$1.03M$1.03M$1.03M$1.03M
Intangibles$584,000$640,000$696,000$751,000$807,000$863,000$918,000$974,000
Total assets$206.42M$190.44M$33.10M$41.79M$52.04M$58.94M$27.36M$38.63M
Current liabilities$19.39M$197.66M$11.83M$9.08M$9.73M$8.57M$7.13M$6.68M
Total liabilities$25.69M$205.12M$22.43M$20.27M$18.43M$17.27M$17.08M$17.73M
Shareholders' equity$180.73M-$14.68M$10.68M$21.52M$33.62M$41.67M$10.28M$20.90M
Shares outstanding109.78M102.72M53.24M53.23M52.81M49.69M34.69M34.69M
Cash flow statement
Operating cash flow-$8.36M-$10.78M-$6.93M-$17.98M-$11.33M-$9.07M-$11.09M-$9.19M
Capital expenditure$33,000———————
Free cash flow-$8.39M———————
Investing cash flow-$1.66M-$137.80M$14.28M$709,000-$12.65M$6.70M$11.35M$11.72M
Financing cash flow$21.58M$168.46M$21,000$6.26M$4.04M——$682,000
Depreciation & amortization$63,000$58,000$57,000$57,000$54,000$55,000$62,000$58,000
Stock-based compensation$7.70M$6.96M-$685,000$1.30M$2.34M$2.89M$2.23M$1.24M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.